CTOs on the Move

IsoPlexis

www.isoplexis.com

 
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.isoplexis.com
  • 35 NorthEast Industrial Road
    Branford, CT USA 06405
  • Phone: 475.221.8402

Executives

Name Title Contact Details

Funding

IsoPlexis raised $25M on 05/14/2019
IsoPlexis raised $20M on 01/09/2020
IsoPlexis raised $50M on 01/07/2021
IsoPlexis raised $85M on 01/07/2021

Similar Companies

Quentis Therapeutics

Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.

Sarepta Therapeutics

Sarepta Therapeutics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Frontier BioSciences

Frontier BioSciences is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.

CollabRx

CollabRx is a clinical decision-support company delivering expert solutions in precision oncology that enable physicians, laboratories, payers, and providers to achieve standardized, evidence-based care and superior clinical outcomes. CollabRx uses information technology to aggregate and contextualize the world`s knowledge on genomics-based medicine with specific insights from the nation`s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.